PolyPid (PYPD)
(Delayed Data from NSDQ)
$3.47 USD
-0.04 (-1.14%)
Updated Oct 11, 2024 12:23 PM ET
After-Market: $3.58 +0.11 (3.17%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PYPD 3.47 -0.04(-1.14%)
Will PYPD be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PYPD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PYPD
PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?
PYPD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PYPD
Buy Rating Affirmed for PolyPid on D-PLEX’s Positive Trial Milestones and Commercial Prospects
PolyPid Buy Rating Affirmed: Promising Clinical Trials and Solid Financial Outlook
PolyPid Nears Completion of Key Phase 3 Trial
PolyPid enrolls last patient for planned unblinded interim analysis in SHIELD II
PolyPid files to sell 3.91M ordinary shares for holders